EXOZYMES INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
EXOZYMES INC. (EXOZ) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $83.35 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-13
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $83.35K.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $94.72K.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $108.68K.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $119.24K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-06-30 | $83.35K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $94.72K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $108.68K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $119.24K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $129.59K 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |